ORGO
Price
$3.21
Change
-$0.17 (-5.03%)
Updated
Feb 21 closing price
Capitalization
374.78M
4 days until earnings call
ZTS
Price
$160.46
Change
+$3.04 (+1.93%)
Updated
Feb 21 closing price
Capitalization
77.48B
67 days until earnings call
Ad is loading...

ORGO vs ZTS

Header iconORGO vs ZTS Comparison
Open Charts ORGO vs ZTSBanner chart's image
Organogenesis Holdings
Price$3.21
Change-$0.17 (-5.03%)
Volume$266.63K
Capitalization374.78M
ZOETIS
Price$160.46
Change+$3.04 (+1.93%)
Volume$3.3M
Capitalization77.48B
ORGO vs ZTS Comparison Chart
Loading...
ORGO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ORGO vs. ZTS commentary
Feb 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ORGO is a Hold and ZTS is a Hold.

Ad is loading...
COMPARISON
Comparison
Feb 23, 2025
Stock price -- (ORGO: $3.21 vs. ZTS: $160.46)
Brand notoriety: ORGO: Not notable vs. ZTS: Notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: ORGO: 53% vs. ZTS: 105%
Market capitalization -- ORGO: $374.78M vs. ZTS: $77.48B
ORGO [@Pharmaceuticals: Other] is valued at $374.78M. ZTS’s [@Pharmaceuticals: Other] market capitalization is $77.48B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.61B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ORGO’s FA Score shows that 1 FA rating(s) are green whileZTS’s FA Score has 1 green FA rating(s).

  • ORGO’s FA Score: 1 green, 4 red.
  • ZTS’s FA Score: 1 green, 4 red.
According to our system of comparison, both ORGO and ZTS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ORGO’s TA Score shows that 4 TA indicator(s) are bullish while ZTS’s TA Score has 5 bullish TA indicator(s).

  • ORGO’s TA Score: 4 bullish, 6 bearish.
  • ZTS’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, ZTS is a better buy in the short-term than ORGO.

Price Growth

ORGO (@Pharmaceuticals: Other) experienced а -13.24% price change this week, while ZTS (@Pharmaceuticals: Other) price change was +1.87% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -1.14%. For the same industry, the average monthly price growth was +77.04%, and the average quarterly price growth was +50.35%.

Reported Earning Dates

ORGO is expected to report earnings on May 07, 2025.

ZTS is expected to report earnings on May 01, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (-1.14% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ZTS($77.5B) has a higher market cap than ORGO($375M). ORGO has higher P/E ratio than ZTS: ORGO (70.25) vs ZTS (32.94). ORGO YTD gains are higher at: 0.312 vs. ZTS (-1.218). ZTS has higher annual earnings (EBITDA): 3.67B vs. ORGO (36M). ZTS has more cash in the bank: 2.04B vs. ORGO (104M). ORGO has less debt than ZTS: ORGO (119M) vs ZTS (6.76B). ZTS has higher revenues than ORGO: ZTS (8.54B) vs ORGO (433M).
ORGOZTSORGO / ZTS
Capitalization375M77.5B0%
EBITDA36M3.67B1%
Gain YTD0.312-1.218-26%
P/E Ratio70.2532.94213%
Revenue433M8.54B5%
Total Cash104M2.04B5%
Total Debt119M6.76B2%
FUNDAMENTALS RATINGS
ORGO vs ZTS: Fundamental Ratings
ORGO
ZTS
OUTLOOK RATING
1..100
968
VALUATION
overvalued / fair valued / undervalued
1..100
71
Overvalued
75
Overvalued
PROFIT vs RISK RATING
1..100
10072
SMR RATING
1..100
8921
PRICE GROWTH RATING
1..100
6263
P/E GROWTH RATING
1..100
1081
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ORGO's Valuation (71) in the Financial Conglomerates industry is in the same range as ZTS (75) in the Pharmaceuticals Generic industry. This means that ORGO’s stock grew similarly to ZTS’s over the last 12 months.

ZTS's Profit vs Risk Rating (72) in the Pharmaceuticals Generic industry is in the same range as ORGO (100) in the Financial Conglomerates industry. This means that ZTS’s stock grew similarly to ORGO’s over the last 12 months.

ZTS's SMR Rating (21) in the Pharmaceuticals Generic industry is significantly better than the same rating for ORGO (89) in the Financial Conglomerates industry. This means that ZTS’s stock grew significantly faster than ORGO’s over the last 12 months.

ORGO's Price Growth Rating (62) in the Financial Conglomerates industry is in the same range as ZTS (63) in the Pharmaceuticals Generic industry. This means that ORGO’s stock grew similarly to ZTS’s over the last 12 months.

ORGO's P/E Growth Rating (10) in the Financial Conglomerates industry is significantly better than the same rating for ZTS (81) in the Pharmaceuticals Generic industry. This means that ORGO’s stock grew significantly faster than ZTS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ORGOZTS
RSI
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
80%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
67%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
59%
MACD
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
56%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
54%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
55%
Advances
ODDS (%)
Bullish Trend 9 days ago
77%
Bullish Trend 2 days ago
59%
Declines
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 5 days ago
54%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
67%
Aroon
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
59%
View a ticker or compare two or three
Ad is loading...
ORGO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RYUTX53.180.07
+0.13%
Rydex Utilities A
RSPMX28.06-0.50
-1.75%
Victory RS Partners Member
FDSVX62.50-1.26
-1.98%
Fidelity Growth Discovery
INRSX16.16-0.44
-2.65%
Macquarie Natural Resources R6
LMOPX35.10-1.04
-2.88%
Patient Opportunity C

ORGO and

Correlation & Price change

A.I.dvisor tells us that ORGO and AMRX have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ORGO and AMRX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ORGO
1D Price
Change %
ORGO100%
-5.03%
AMRX - ORGO
30%
Poorly correlated
-0.51%
ACET - ORGO
29%
Poorly correlated
-2.66%
HROW - ORGO
28%
Poorly correlated
-3.92%
AMPH - ORGO
27%
Poorly correlated
-0.06%
HTSUF - ORGO
26%
Poorly correlated
N/A
More

ZTS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZTS has been loosely correlated with SNDL. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if ZTS jumps, then SNDL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZTS
1D Price
Change %
ZTS100%
+1.93%
SNDL - ZTS
33%
Loosely correlated
+0.57%
ACET - ZTS
31%
Poorly correlated
-2.66%
EVO - ZTS
27%
Poorly correlated
-0.45%
ORGO - ZTS
26%
Poorly correlated
-5.03%
HLN - ZTS
26%
Poorly correlated
+1.82%
More